Clinical outcome for patients with dedifferentiated chondrosarcoma: a report of 9 cases at a single institute
© Yokota et al.; licensee BioMed Central Ltd. 2012
Received: 2 January 2012
Accepted: 5 December 2012
Published: 10 December 2012
Dedifferentiated chondrosarcomas consist of two distinguishable components: low-grade chondrosarcoma components and high-grade dedifferentiated components.
Materials and methods
Nine cases (4 males, 5 females) of dedifferentiated chondrosarcoma were treated in our institute. The average age was 58.6 (range, 37–86) years. The tumor location was the long bone in 7 cases (femur, n=5; humerus, n=1; tibia, n=1) and the pelvic bone in 2 cases. The average time from appearance of symptoms to treatment was 9.4 (range, 1–40) months.
Results and discussion
On plain radiographs, matrix mineralization was seen in all 9 cases (100%). Bone destruction was observed in 5 of 9 cases (56%), while pathological fracture was seen in one femur case (11%). Lung metastasis was observed in all cases (initially in 5 cases; during the treatment course in 4 cases). Surgery was performed in 8 cases, with local recurrence occurring in 2 of those cases (time to recurrence, 2 and 10 months). Chemotherapy was administered in 4 cases, but did not result in significant improvement. All 9 cases died of lung metastases, with a median survival time of 10 (range, 3.4-18.8) months. The presence of initial metastasis at diagnosis was a significant unfavorable prognostic factor.
The prognosis of dedifferentiated chondrosarcoma is dismal. With the lack of convincing evidence of the benefit of chemotherapy, complete surgical excision is the initial recommended treatment.
Dedifferentiated chondrosarcomas consist of two distinguishable components: low-grade chondrosarcoma components and high-grade dedifferentiated components. This group of cancers was first described in 1971. The dedifferentiated components have varying features, including features of undifferentiated sarcomas, osteosarcomas, angiosarcomas, fibrosarcomas, rhabdomyosarcomas, leiomyosarcomas, and giant cell tumors. Dedifferentiated chondrosarcomas are highly malignant with a very poor prognosis[3, 4]. Surgery is the primary treatment modality, and chemotherapy has been adapted for use in selected cases with dedifferentiated chondrosarcoma[2, 4, 5]. In the current report, a series of dedifferentiated chondrosarcoma cases treated in our institute is examined, with a focus on identification of prognostic factors.
Materials and methods
Clinical information of cases with dedifferentiated chondrosarcoma
Term of symptom
Local recurrence (time from surgery)
Time to lung metastasis
DOD (3.4 m)
+ (10 m)
DOD (14.1 m)
DOD (5.0 m)
+ (2 m)
DOD (10 m)
DOD (9.1 m)
DOD (18.8 m)
DOD (14.0 m)
DOD (6.7 m)
DOD (5.0 m)
Plain radiographs taken at the initial visit to our institute were assessed. They were evaluated with respect to matrix mineralization, bone destruction, and the presence of fracture. The presence of extraskeletal extension was assessed by magnetic resonance imaging (MRI). Surgical treatment was performed by either resection alone or resection followed by implantation of an endoprosthesis. Chemotherapy was administered to select cases.
The survival estimates were determined by Kaplan-Meier analysis, while the survival differences according to clinical parameters (lung metastasis, local recurrence, and location) were evaluated by the log-rank test. A P value of less than 0.05 was considered to indicate statistical significance.
Summary of clinical symptoms and images in cases of dedifferentiated chondrosarcoma
Location (long bone /trunk)
On plain radiographs, matrix mineralization was observed in all 9 cases (100%). Bone destruction was detectable in 5 of the 9 cases (56%). Pathological fracture was observed in 1 femur case (11%). On MRI, extraskeletal extension was seen in 6 of the 9 cases (67%). All of the cases with bone destruction on plain radiographs had extraskeletal extension on MRI (Table2).
Eight of the nine cases were managed with surgery (89%), while the other one case received non-surgical palliative care only. This latter patient was an 86-year-old woman with dedifferentiated chondrosarcoma in the femur who refused to undergo amputation. Among the 8 cases who underwent surgery, 6 cases were given a wide surgical margin (75%), 1 case was given a marginal margin (13%), and 1 case underwent intralesional resection (13%). In the long bone cases, wide resection was performed in all 6 cases. In contrast, in the pelvic bone cases, 1 case was given a marginal margin, while the other case underwent intralesional resection (Table1).
Chemotherapy was given to 4 patients following surgical tumor resection. The chemotherapy regimen consisted of adriamycin, ifosfamide, cisplatin, and methotrexate.
Lung metastasis was observed in all cases (initially in 5 cases; during the treatment course in 4 cases). In one case, bone metastasis was seen in addition to the lung metastasis. Time to lung metastasis ranged from 4 to 15 months, with an average of 9.5 months. Local recurrence following resection occurred in 2 of the 8 surgery cases, at 2 and 10 months. Both of these local recurrence cases had undergone amputation (Table1).
Dedifferentiated chondrosarcoma is known to have a poor prognosis. Median survival has been as short as 6 months, and 5-year survival rates may be as low as 10% to 13%. Patients rarely survive for more than 2 years[3, 4]. Consistent with the reported unfavorable prognosis, all current cases died of lung metastases, with a median survival time of only 10 months (range, 3.4 to 18.8 months). In two very recent reports, the median survival time was 7.5 months and 1.4 year, and the overall 5-year survival rate was 7.1% and 24%, respectively. The prognosis of dedifferentiated chondrosarcoma has shown a slow improvement trend over time, presumably due to earlier diagnosis and improved staging and treatment.
Metastasis, especially to the lung, is the most important treatment problem in patients with dedifferentiated chondrosarcoma[5–7]. In the current study, the presence of metastases at diagnosis was a significant unfavorable prognostic factor. Chemotherapy is an option for control of metastatic lesions. However, the value of chemotherapy for cases with dedifferentiated chondrosarcoma has not been supported[2, 4]. In addition to the lack of convincing evidence of the benefit of chemotherapy, the toxicity of chemotherapy experienced by older patients with dedifferentiated chondrosarcoma generally rules it out as a standard treatment. However, in a previous report, 2 out of 13 patients with dedifferentiated chondrosarcoma experienced a good response to chemotherapy, demonstrating more than 90% necrosis. These results suggest a possible benefit of chemotherapy for some patients with dedifferentiated chondrosarcoma.
The prognosis of patients with dedifferentiated chondrosarcoma can be improved by an accurate preoperative diagnosis. Characteristically on plain radiographs, a combined pattern composed of the aggressive parts of dedifferentiated chondrosarcoma components and the less aggressive parts of well-differentiated chondrosarcoma components suggests dedifferentiated chondrosarcoma[8, 9]. Reflecting the aggressive nature of dedifferentiated chondrosarcoma, osteolytic lesions associated with cortical destruction have been reported in the majority of cases on plain radiographs. In the current study, bone destruction was present in about half of the cases on plain radiographs, and all of these cases demonstrated extraskeletal extension on MRI. The presence of matrix mineralization, indicative of a cartilaginous tumor, accompanied by bone destruction of an aggressive nature may suggest a diagnosis of dedifferentiated chondrosarcoma based on plain radiographs.
It is important to distinguish between conventional chondrosarcoma and dedifferentiated chondrosarcoma, considering the greatly different prognosis. A pathological diagnosis would be inaccurate if the biopsy sample contained just one component of dedifferentiated chondrosarcoma. Therefore, a carefully planned biopsy based upon MRI, assessing each component of dedifferentiated chondrosarcoma, is essential. Even if only one component—either a conventional chondrosarcoma component or a dedifferentiated component—is detected in the pathological sample, possible dedifferentiated chondrosarcoma should be considered in cases in whom plain radiographs show matrix mineralization with a destructive aggressive feature.
Local control by surgery does not appear to be related to prognosis[5–7]. This observation seems to emphasize the importance of not only local control, but also control regarding metastasis, which is directly associated with the prognosis. However, surgical treatment for local control is still an important procedure for dedifferentiated chondrosarcoma. Local recurrence has been reported in up to 50% of cases after excision, with much better local control when there is adequate, or wide, resection[3–5]. In the current study, local recurrence was seen in 2 out of 6 cases treated with wide resection, including 1 case in the tibia and 1 case in the humerus. Since the tibia and humerus are close to essential vessels, the creation of an adequate surgical margin intended to prevent local control may be difficult.
Regarding the pathogenesis of dedifferentiated chondrosarcoma, no structural or numerical chromosomal aberrations that are highly specific for dedifferentiated chondrosarcomas have been identified. However, some evidence has suggested clustering of breakpoints in specific regions of 6q13-22 and 9p21-24 in dedifferentiated chondrosarcoma. High-grade dedifferentiated components have been shown to have a higher malignant potential than low-grade chondrosarcoma components, with increased proliferation as demonstrated by expression of Ki-67 and proliferating cell nuclear antigen. The plasminogen activator system is a key regulator of invasion and tumor angiogenesis. Plasminogen activator inhibitor 1 (PAI-1) acts as an inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). In dedifferentiated chondrosarcoma, high-grade dedifferentiated components display diffuse coexpression of t-PA, u-PA, and PAI-1. Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that are principally involved in the breakdown of the extracellular matrix, as well as in tumor angiogenesis. Upregulation of MMP2 and MT1-MMP has been reported in high-grade malignant cartilaginous tumors, as well as in the high-grade dedifferentiated component of dedifferentiated chondrosarcoma.
The current study describes a series of dedifferentiated chondrosarcoma cases treated in our institute. The presence of initial metastasis at diagnosis was a significant unfavorable prognostic factor. The prognosis of dedifferentiated chondrosarcoma remains dismal. With the lack of convincing evidence of the benefit of chemotherapy for dedifferentiated chondrosarcoma, including what constitutes standard treatment, its use in this patient population remains controversial. Complete surgical excision should be the initial treatment for patients with a dedifferentiated chondrosarcoma, with chemotherapy reserved for palliative purposes.
Magnetic resonance imaging.
The patient’s families were informed that data from the case would be submitted for publication, and gave their consent.
The English used in this manuscript was revised by Miss K. Miller (Royal English Language Centre, Fukuoka, Japan).
- Dahlin DC, Beabout JW: Dedifferentiation of low-grade chondrosarcomas. Cancer. 1971, 28: 461-466. 10.1002/1097-0142(197108)28:2<461::AID-CNCR2820280227>3.0.CO;2-U.View ArticlePubMed
- Bruns J, Fiedler W, Werner M, Delling G: Dedifferentiated chondrosarcoma-a fatal disease. J Cancer Res Clin Oncol. 2005, 131: 333-339. 10.1007/s00432-004-0648-6.View ArticlePubMed
- Frassica FJ, Unni KK, Beabout JW, Sim FH: Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases. J Bone Joint Surg Am. 1986, 68: 1197-1205.PubMed
- Mercuri M, Picci P, Campanacci L, Rulli E: Dedifferentiated chondrosarcoma. Skeletal Radiol. 1995, 24: 409-416. 10.1007/BF00941235.View ArticlePubMed
- Grimer RJ, Gosheger G, Taminiau A, Biau D, Matejovsky Z, Kollender Y, San-Julian M, Gherlinzoni F, Ferrari C: Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer. 2007, 43: 2060-2065. 10.1016/j.ejca.2007.06.016.View ArticlePubMed
- Dickey ID, Rose PS, Fuchs B, Wold LE, Okuno SH, Sim FH, Scully SP: Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J Bone Joint Surg Am. 2004, 86-A: 2412-2418.PubMed
- Capanna R, Bertoni F, Bettelli G, Picci P, Bacchini P, Present D, Giunti A, Campanacci M: Dedifferentiated chondrosarcoma. J Bone Joint Surg Am. 1988, 70: 60-69.PubMed
- Mitchell AD, Ayoub K, Mangham DC, Grimer RJ, Carter SR, Tillman RM: Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br. 2000, 82: 55-61. 10.1302/0301-620X.82B1.9020.View ArticlePubMed
- Littrell LA, Wenger DE, Wold LE, Bertoni F, Unni KK, White LM, Kandel R, Sundaram M: Radiographic, CT, and MR imaging features of dedifferentiated chondrosarcomas: a retrospective review of 174 de novo cases. RadioGraphics. 2004, 24: 1397-1409. 10.1148/rg.245045009.View ArticlePubMed
- O’Malley DP, Opheim KE, Barry TS, Chapman DB, Emond MJ, Conrad EU, Norwood TH: Chromosomal changes in a dedifferentiated chondrosarcoma: a case report and review of the literature. Cancer Genet Cytogenet. 2001, 124: 105-111. 10.1016/S0165-4608(00)00335-6.View ArticlePubMed
- Simms WW, Ordóñez NG, Johnston D, Ayala AG, Czerniak B: p53 expression in dedifferentiated chondrosarcoma. Cancer. 1995, 76: 223-227. 10.1002/1097-0142(19950715)76:2<223::AID-CNCR2820760210>3.0.CO;2-4.View ArticlePubMed
- Dellas C, Loskutoff DJ: Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost. 2005, 93: 631-640.PubMed
- Häckel C, Czerniak B, Ayala AG, Radig K, Roessner A: Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Cancer. 1997, 79: 53-58. 10.1002/(SICI)1097-0142(19970101)79:1<53::AID-CNCR8>3.0.CO;2-N.View ArticlePubMed
- Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993, 4: 197-250.PubMed
- Sakamoto A, Oda Y, Iwamoto Y, Tsuneyoshi M: Expression of membrane type 1 matrix metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma. J Cancer Res Clin Oncol. 1999, 125: 541-548. 10.1007/s004320050314.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.